USFDA10 Oct 2025, 01:43 pm
Emcure Pharmaceuticals' Manufacturing Facility Passes US FDA Inspection Without Any Observation
AI Summary
Emcure Pharmaceuticals Ltd. has announced the successful completion of a US FDA surveillance inspection at their manufacturing facility located at Kadu, Surendranagar, Gujarat, India. The inspection, which took place from October 06, 2025 to October 10, 2025, concluded without any observations. This is a significant development, highlighting the company's commitment to maintaining high standards of quality and compliance.
Key Highlights
- US FDA inspection conducted at Emcure Pharmaceuticals' manufacturing facility in Surendranagar, Gujarat, India
- Inspection concluded without any observations
- Demonstrates the company's commitment to quality and compliance